Pathogenesis Clues from the Early Clinical Presentation of 300 Hospitalized COVID-19 Patients

Feng Yu  
Shanghai Putuo District People's Hospital

Xuemei Deng  
WuHan Third Hospital, Tongren Hospital of Wuhan University

Li Ni  
Shanghai Putuo District People's Hospital

Wei Li  
Wuhan Third Hospital, Tongren Hospital of Wuhan University

Ping Yan  
Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Mian Huang  
Wuhan Third Hospital, Tongren Hospital of Wuhan university

xiongbiao wang (✉ xiongbiao6@yahoo.com)  
Shanghai PuTuo District Center Hospital

Research article

Keywords: COVID-19, Clinical characteristics, Lymphocytes, Early symptoms, Pathogenesis.

DOI: https://doi.org/10.21203/rs.3.rs-42484/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The global spread of the 2019 coronavirus disease (COVID-19) has lasted more than half a year. Except for the gene sequence and viral structure of SARS-CoV-2, its clinical characteristics, pathological mechanisms and corresponding measures have not been fully revealed. We aimed to speculate about the possible pathological mechanism from the early clinical manifestations of patients with COVID-19.

**Methods:** The onset symptoms, laboratory examinations and CT findings on admission of 300 patients in two wards of Wuhan Third Hospital from January 28 to March 15 were analyzed retrospectively.

**Results:** There was no difference in incidence between men and women, but women were hospitalized later after onset. Upper respiratory symptoms and sputum were rare. The incidence of fever was 71%. Blood lymphocyte counts were decreased significantly on admission and were related to the severity of the disease. In moderate patients without hypoxia, thrombocytopenia occurred in 12.37%, CRP rose in 64.43%, BUN was elevated in 20.62%, creatinine rose in 17.53%, D-dimer was elevated in 74.74%, and creatine kinase and α-hydroxybutyrate dehydrogenase were elevated in 45.36% and 54.12% of patients, respectively. Early CT showed a small amount of infiltration in the subpleural and lateral zones of the lung and thickening of the interlobular septum. Approximately 5 days later, infiltration was worse in some of the patients, and the proportion of involvement of the affected lung was negatively correlated with the lymphocyte count.

**Conclusions:** There was no sex difference in patients with SARS-CoV-2 infection. Alveolar cells and T lymphocytes may be the main targets of the virus, and apoptosis may be the primary mechanism of pathogenesis. The virus entering the lung may be transmitted through lymph or blood vessels rather than directly dispersing through the respiratory tract. Early damage to multiple organs may be caused by the immune response.

Background

After badly affecting China for more than three months, the 2019 coronavirus disease (COVID-19) outbreaks have abated in China; however, the threat from COVID-19 is not over, and COVID-19 is now prevalent all over the world. As of July 6, there were more than 11.7 million cases of infection and 539554 deaths worldwide. Before a vaccine for COVID-19 is available, quarantine is a passive defensive measure that has to be taken. However, long-term quarantine is also associated with many problems, such as social and economic problems. The standardization of epidemic prevention measures is currently the main problem. How can infected individuals be identified and quarantine measures be implemented as soon as possible? Although laboratory tests (nucleic acid tests and antibody tests) have been greatly improved, the clinical recognition and judgment by doctors is still very important, especially when influenza and the common cold can occur in the same period and complicate the diagnosis.
The history of COVID-19 is quite short; it was found and identified in early January 2020. The virus 2019-nCoV causes a lower respiratory tract disease that was initially called novel coronavirus pneumonia by the Chinese government. The disease is now officially named COVID-19 by the World Health Organization (WHO). Moreover, 2019-nCoV was renamed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. On 11 March 2020, the WHO characterized COVID-19 as a pandemic. To minimize the spread of SARS-CoV-2, China locked down Wuhan and nearby cities beginning January 23, 2020. The strong measures, including suspension of all urban transportation, was apparently successful in preventing further spreading of SARS-CoV-2 to other cities. The peak of infection occurred at the end of January 2020, and the morbidity decreased dramatically after mid-February [1]. Until March, only sporadic cases were reported. However, COVID-19 is very severe worldwide, and the WHO declared recently that COVID-19 may be present in the human population forever, which means that the fight against SARS-CoV-2 will last. Two major problems still trouble us: there is no vaccine to prevent and no drug to cure COVID-19. The present treatments are symptomatic treatments based on previous experience, but identification of additional measures should be of great importance, as COVID-19 is unique and the pathogenesis is quite different from severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) or others.

The recognition of disease first comes from clinical manifestations, especially early clinical manifestations, which can better reflect the characteristics of diseases and lay a foundation for understanding the pathological mechanism and for making treatment plans. Studies on the natural history of SARS-CoV-2 infection in humans are urgently needed. The WHO and International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) designed a case report form specific for COVID-19 that can provide clinical data anonymously and in a standardized manner to obtain accurate clinical manifestations and natural history data for this purpose. The features of the clinical manifestations of COVID-19 have been described in many reports, most of which are based on early data from January 2020 [2–4]. However, these reports are only the beginning of a comprehensive and systematic study. Here, we report clinical data from a cohort of COVID-19 patients and propose suggestions based on these clinical manifestations.

**Methods**

**Patients**

This study only retrospectively reviewed a cohort of patients who were admitted to the Wuhan Third Hospital in the Guanggu District, which was a referral center for local COVID-19 patients diagnosed in the public health center in Wuhan, China. All patients were confirmed to have SAS-CoV-2 by testing before admission. The test was performed on samples from nasopharyngeal swabs using real-time reverse transcriptase PCR as described previously. Due to the sudden outbreak of COVID-19 in late January, the medical system in Wuhan was caught off guard, there were not enough infectious wards, and a large number of patients remained outside of the hospital. Our hospital was temporarily restructured as a designated COVID-19 hospital. On the day of opening (Jan 28), all beds were filled immediately. A total of
332 patients in two adult wards of the hospital from January 28 to March 15 were enrolled in this study. Due to incomplete data from 32 patients, 300 patients were included in this study. The data collected included demographic, clinical symptom, and laboratory and chest CT findings. The severity of pneumonia in these patients was assessed according to the Guidelines for Diagnosis and Management of COVID-19 (6th edition, in Chinese) issued by the National Health Commission of China [5].

**CT image acquisition**

All CT scans were obtained using one of the following scanners: SOMATOM Perspective, SOMATOM Spirit, or SOMATOM Definition AS+ (Siemens Healthineers, Forchheim, Germany) with patients in the supine position. Scans were performed from the level of the upper thoracic inlet to the inferior level of the costophrenic angle, and the following parameters were used: detector collimation widths 64 × 0·6 mm, 128 × 0·6 mm, 64 × 0·6 mm, and 64 × 0·6 mm; and tube voltage 120 kV. The tube current was regulated by an automatic exposure control system (CARE Dose 4D; Siemens Healthineers). Images were reconstructed with a slice thickness of 1–5 mm or 1 mm and an interval of 1–5 mm or 1 mm, respectively. The reconstructed images were transmitted to a workstation, and a picture archiving and communication system (PACS) was used for multiplanar reconstruction post processing.

**Image interpretation**

Images from patients seen at Wuhan Third Hospital were analyzed by two respiratory doctors (FY with 25 years of experience and XW with 34 years of experience). All Digital Imaging and Communications in Medicine (DICOM) images from the CT studies were analyzed without access to clinical or laboratory findings. The evaluators independently and freely assessed the CT features using both axial CT images and multiplanar reconstruction images. After separate evaluations, any disagreements in the results were resolved by discussion and consensus.

**Statistics**

Statistical analysis was performed using SPSS Software version 25.0 for Windows (SPSS Inc., Chicago, IL, USA). Descriptive analyses were conducted for demographic, clinical, and laboratory data.

**Results**

**Characteristics of sex, age and the days from onset of symptoms to first hospital admission**

We did not find a difference in morbidity between men and women, as in previous reports [6–8], which is also different from that in MERS-CoV [9]. However, our result is consistent with 50466 case analyses from Chinese Center for Disease Control and Prevention [2]. The average age of the patients was approximately 60 years old in both men and women. The variation of the days from onset to first admission was quite large, usually an early onset of symptoms with a delay in hospital admission, which represented the shortage of medical resources during late January and early February. The shortage was
relieved very quickly as many referral hospitals were established, and the incidence of disease also decreased. Noticeably, the median time from onset of symptoms to hospital admission was significantly longer for women (Table 1). An analysis of 36 families with cluster-related infection revealed that the time of onset was essentially the same for all patients (data not shown). Members of one family were often admitted to several hospitals. The main reasons for male patients being hospitalized earlier may be that women’s resilience to symptoms was higher than in men, and men had more severe disease and more comorbidities [10].

| N  | Sex   | Age (S ± SD)          | Days from onset to admission(d ± SD) |
|----|-------|-----------------------|-------------------------------------|
| 151| Male  | 62.4189 ± 12.56061    | 10.4189 ± 5.2112                    |
| 149| Female| 60.87077 ± 11.2789    | 14.1044 ± 5.3645                    |

Table 1
The characteristics of sex, age and the days from onset of symptoms to first hospital admission

Most of the patients with severe and critical disease were elderly—over 60 years old.

Because patients with mild disease were admitted to the shelter hospital, the patients in this group all had moderate, severe and critical disease based on the guidelines. Similar to previous reports, the patients with severe and critical illness were mainly elderly patients over 60 years old, and there was no difference in the sex distribution of patients (Table 2). The clinical manifestations of COVID-19 in older patients were systemic symptoms and more severe radiological abnormalities (data not shown).

| Age | Male(N) | Female(N) |
|-----|---------|-----------|
|     | Moderate| Severe    | Critical  | Moderate| Severe| Critical |
| < 60| 29      | 17        | 3         | 43      | 14   | 2        |
| ≥ 60,<70| 35  | 21        | 1         | 24      | 11   | 4        |
| ≥ 70| 42      | 13        | 3         | 21      | 14   | 3        |
| 106 | 51      | 7         | 88        | 39      | 9    |          |

Table 2
Disease severity was directly related to patient age

Early symptoms included fewer upper respiratory symptoms and less sputum
Most patients in this group had been treated in the outpatient department several times, and their symptoms at the time of onset were recorded. As shown in Fig. 1, fever, cough and fatigue were the three main symptoms at onset, while the incidence of upper respiratory symptoms (nasal obstruction 1.34%, runny nose 2.34%, and sore throat 7.67%) was lower than the incidence of diarrhea 15.67%. In all 300 cases, more than 71% of the patients had fever, 58.3% of the patients had asthenia, and many patients had chills, but headache, dizziness, muscle pain, chills and other symptoms were rare. The fever type was classified as uncertain, low, medium and high. Most of the patients had dry cough symptoms in the early stage, occasionally accompanied by expectoration. Hemoptysis was rare.

**Abnormalities in laboratory data occurred in some non-hypoxemic patients**

The laboratory data of the patients at admission, including routine blood examination, C-reactive protein (CRP), liver and kidney function, coagulation and other indicators, are presented in Table 3. We also found that the lymphocyte count in patients was related to the severity of the disease. A lymphocyte count less than $0.8 \times 10^9$/L was more likely to cause critical illness (Fig. 2). Moreover, thrombocytopenia, reduced renal function, hypoalbuminemia, elevated D-dimer and elevated CRP, creatine kinase and α-hydroxybutyrate dehydrogenase were also found in COVID-19 patients and were linked to progressive infection (Table 3). It is very interesting to note that there were abnormal myocardial enzyme spectra, liver enzyme spectra and coagulation markers in moderately ill patients who did not have hypoxemia.
### Table 3
Laboratory findings on admission

|                | ordinary (194) | severe (90) | critical (16) |
|----------------|----------------|-------------|---------------|
|                | N (%)          |             |               |
| HB ↓           | 52 (26.8)      | 48 (53.33)  | 14 (87.5)     |
| WBC ↑          | 147 (75.77)    | 70 (77.78)  | 14 (87.5)     |
| Lymphocytes account ↓ | 85 (43.81)    | 73 (81.11)  | 13 (81.25)    |
| Platelet ↓     | 24 (12.37)     | 43 (47.78)  | 9 (56.25)     |
| CRP ↑          | 125 (64.43)    | 82 (91.11)  | 13 (81.25)    |
| Procalcitonin ↑| 19 (9.79)      | 20 (22.22)  | 10 (62.5)     |
| D-Dimer ↑      | 145 (74.74)    | 73 (81.11)  | 16 (100)      |
| ALT ↑          | 51 (26.29)     | 34 (37.78)  | 3 (18.75)     |
| AST ↑          | 55 (28.35)     | 40 (44.44)  | 3 (18.75)     |
| Albumin ↓      | 190 (97.94)    | 90 (100)    | 16 (100)      |
| BUN ↑          | 40 (20.62)     | 27 (30)     | 2 (12.5)      |
| creatinine ↑   | 34 (17.53)     | 25 (27.78)  | 2 (12.5)      |
| lactic acid    | 96 (49.48)     | 43 (47.78)  | 11 (68.75)    |
| creatine kinase ↑ | 88 (45.36)   | 44 (48.89)  | 12 (75)       |
| α-Hydroxybutyrate Dehydrogenase ↑ | 105 (54.12) | 68 (75.56) | 13 (81.25) |

**Subpleural lesions were typical manifestations on lung CT in the early stage of disease**

According to the analysis of the patients’ first lung CT examinations, most were performed within 5 days after onset, and the images were characterized by single or multiple subpleural ground-glass opacities, consolidation, and involvement of less than 50% of the lung. After admission, the lung CT findings showed that most of the patients had reticulation, and a few patients had significantly increased infiltrative shadows, even involving the whole lung (data not shown). Moreover, we observed a relationship between lymphocyte counts and lung CT imaging findings, as shown in Fig. 3. The lymphocyte count was negatively correlated with lung injury ($R = 0.426$).

**Discussion**
In this study, we retrospectively analyzed the early clinical manifestations of 300 hospitalized COVID-19 patients. The main impressions of the early clinical manifestations are that there is no sex bias in the incidence; that rare upper respiratory symptoms, age and the lymphocyte counts relate to disease severity, peripheral pulmonary involvement and lymphopenia; and that multisystem damage occurs in some moderately ill patients without hypoxia. Although many papers have been published recently, the concrete pathogenesis of COVID-19 has not yet been identified. What could we learn from the early clinical features of COVID-19? Clinical features provide many clues for pathogenesis.

The mode of transmission of the virus is thought to be largely by inhalation of respiratory droplets. Did the virus in the affected lung lesion come from airway spread? Although the nasopharynx mucosa was believed as first infected with SARS-CoV-2, the symptoms involving the upper respiratory tract occur less often, which is consistent with previous reports [7, 11–13] and indicates that the upper respiratory tract inflammation was mild. Moreover, the distribution of lung lesions was characterized by subpleural and lateral zones in the early stage, which suggested that the infection did not spread along the airway. Transmission of SARS-CoV-2 through contaminated surfaces might be possible [14], while aerosols are currently not considered the primary mode of transmission [15]. The above points suggested that the lung lesion may be infected as a result of SARS-CoV-2 moving along lymphatics or blood vessels, as well as invading other target tissues. We propose that the virus might pass through the mucous membranes of the nasal passages, larynx or skin and then enter the blood, causing viremia. The virus attacks the targets, including the lungs and T lymphocytes. It is very interesting to find that the virus could be detected in the upper respiratory tract with no symptoms and mild inflammation within the bronchi and bronchioles, along with prominent mucosal edema within the bronchial mucosa [16]. It seems that the upper respiratory tract, trachea, bronchi and bronchioles were not the targets of the virus, although their mucous membrane expressed angiotensin converting enzyme II (ACE2).

The early pathogenesis of COVID-19 is still unclear. The primary cells affected by SARS-CoV-2 may be both alveolar cells and T lymphocytes. Apoptosis could be the main early event. The first evidence comes from clinical studies. The lymphocyte count is negatively related to disease severity and is commonly considered a marker of prognosis [2, 17, 18]. This phenomenon also suggests that alveolar cells and T lymphocytes are both targets of SARS-CoV-2, and the T lymphocytes count could reflect the alveolar cell counts. The main evidence should be derived from the histopathologic features: diffuse alveolar damage (DAD) [19] and T-lymphocyte apoptosis in lymphoid organs, especially the spleen [20, 21]. This is similar to MERS-CoV that can efficiently infect T cells from the peripheral blood and from human lymphoid organs and induce apoptosis in T cells, which involves the activation of both the extrinsic and intrinsic apoptosis pathways [22]. The number of CD4-positive T cells and CD8-positive T cells in the spleen and lymph nodes decreased, they were degenerated and necrotic, and macrophages proliferated in the spleen.

The immune response may explain the early clinical manifestations. The initial symptoms are mainly fever, cough, and lymphopenia. Increased values of liver enzymes, lactate dehydrogenase (LDH), muscle enzymes, coagulation factors and C-reactive protein can be found in some mildly ill patients without hypoxia in the early stage, which means that these abnormal changes were not secondary damage from
hypoxia or secondary infection. The possible pathogenesis may be damage from the virus directly or by immune response. The possibility of an immune response should be greater than the direct invasion of the virus. The most direct evidence is the result of autopsy. No SARS-CoV-2 was detected in the heart, liver, kidney, spleen, pancreas, or gastrointestinal tract by immunohistochemistry and PCR [23]. Transcriptome sequencing of RNA isolated from bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cell (PBMC) specimens of COVID-19 patients revealed distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients and highlighted the association between COVID-19 pathogenesis and excessive cytokine release, such as that of CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B [24].

It has also been hypothesized that the virus might use ACE2 as a receptor, similar to SARS-CoV [25]. ACE2 is also expressed on many different cell types, including cardiac, renal, intestinal, endothelial, and gut cells [26, 27]. As no virus was found in these tissues [21], the receptor for SARS-CoV-2 has not been fully elucidated. SARS-CoV-2 may use ACE2 for entry and the serine protease TMPRSS2 for S protein priming [28].

Our study has several limitations inherent to its design. First, this was a retrospective study with the potential of incomplete and possible variation of data recording from the primary care providers. Second, patients with mild disease were not included. Third, much larger cohorts are needed.

COVID-19 is a new disease, our knowledge is gradually updated based on the ongoing research findings and clinical practice experience. The current study is a start to our understanding of the clinical presentation and spectrum of the disease for greater precision of estimates and an initial step to performing prognostic and risk factor analyses. It was expected that the human-to-human transmission toxicity of COVID-19 would be reduced [29] because a genetic bottleneck of RNA viruses often occurs in the process of respiratory droplet transmission; however, the real world scenario is still serious. The spread of COVID-19 could not be stopped.

**Abbreviations**

COVID-19
2019 coronavirus disease; WHO: World Health Organization; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SARS: Severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; CRP: C-reactive protein; HB: Hemoglobin; WBC: White blood cell; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; ACE2: Angiotensin converting enzyme II;

**Declarations**

**Acknowledgments**

Not applicable
Authors’ contributions

XW and MH conceived and designed the research. FY and XD analyzed data and wrote the paper. LN, WL and PY contributed to data collection. All authors read and approved the final manuscript.

Funding

Not applicable

Availability of data and materials

The datasets generated and/or analyzed are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Wuhan Third Hospital, and written informed consent was waived because of the retrospective nature of the study.

Consent for publication

Not applicable.

Competing interests

The authors have declared no conflict of interest.

Author details

1Department of Respiratory Medicine, Shanghai Putuo District People’s Hospital, Shanghai, China.
2Department of Neurology, WuHan Third Hospital, Tongren Hospital of Wuhan University, No.216 Guanshandadao, Wuhan 430060, Hubei province, China. 3Department of Orthopedics, WuHan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, Hubei, China. 4Department of infective medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. 5Department of Respiratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, No.164 LanXi Road, Shanghai 200062, China.

References
1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) —China, 2020. China CDC Weekly. 2020;2(8):113–22.

2. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol. 2020;92(6):612–17.

3. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life sciences. 2020;63(3):364–74.

4. Meo SA, Alhowikan AM, Al-Khaiwi T, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W. Ahmed N. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–19.

5. The National Health Commission of the People's Republic of China home page http://www.nhc.gov.cn.

6. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):108.

7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

8. Giwa A, Desai A. Novel coronavirus COVID-19: an overview for emergency clinicians. Emerg Med Pract. 2020;22(2 Suppl 2):1–21.

9. Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin. 2016;31(1):81–4.

10. Sharma G, Volgman AS, Michos ED. Sex Differences in Mortality from COVID-19 Pandemic: Are Men Vulnerable and Women Protected? JACC Case reports. 2020.

11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.

12. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol. 2020.

13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

14. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020;395(10224):e39.

15. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clinical experimental pediatrics. 2020;63(4):119–24.

16. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153(6):725–33.
17. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal transduction targeted therapy. 2020;5(1):33.

18. Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, Le A, Li J, Wan L. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19. J Infect Dis. 2020.

19. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine. 2020;8(4):420–22.

20. Xu X, Chang XN, Pan HX, Su H, Huang B, Yang M, Luo DJ, Weng MX, Ma L, Nie X. [Pathological changes of the spleen in ten patients with coronavirus disease 2019(COVID-19) by postmortem needle autopsy]. Zhonghua Bing Li Xue Za Zhi. 2020;49(6):576–82.

21. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, Mou HM, Wang LH, Zhang HR, Fu WJ, et al. [A pathological report of three COVID-19 cases by minimal invasive autopsies]. Zhonghua Bing Li Xue Za Zhi. 2020;49(5):411–17.

22. Chu H, Zhou J, Wong BH, Li C, Chan JF, Cheng ZS, Yang D, Wang D, Lee AC, Li C, et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. J Infect Dis. 2016;213(6):904–14.

23. Wu J, Lu AD, Zhang LP, Zuo YX, Jia YP. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019; 40(1):52–57.

24. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes infections. 2020;9(1):761–70.

25. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.

26. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203(2):622–30.

27. Albini A, Di Guardo G, Noonan DM, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg Med. 2020.

28. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80. e8.

29. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R, Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls. edn. Treasure Island (FL); 2020.
Figure 1

Clinical characteristics at onset (no. of cases): The symptoms are presented as numbers of cases.
Figure 2

Lymphocyte count was associated with disease severity: The findings are presented as lymphocyte counts and disease subtypes.
Figure 3

The relationship of lung infiltrate involvement with lymphocyte count.